AZ gets China nod for Tagrisso in first-line lung cancer

AstraZeneca has scored another approval for one of its new drugs in China, this time getting a green light for Tagrisso as a first-line treatment for adults with EGFR-positive non-small cell lung cancer (NSCLC).